Testing effectiveness (Phase 2)Study completedNCT02316106
What this trial is testing
Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 123